HAYA Therapeutics

HAYA Therapeutics is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics to reprogram disease-driving cell states for chronic and age-related diseases. They are developing a pipeline of RNA-guided therapies, with their lead candidate HTX-001 for heart failure. HAYA's platform leverages insights into the regulatory genome to create safer, more effective treatments.

Funding Round: Series A

Funding Amount: $65M

Date: 08-May-2025

Investors: Sofinnova Partners, Earlybird Venture Capital, Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, Apollo Health Ventures, Longview Ventures, 4see ventures, BERNINA Bioinvest, Schroders Capital

Markets: Biotech, Therapeutics, Healthcare

HQ: Lausanne, Switzerland

Founded: 2017

Website: https://www.hayatx.com/

LinkedIn: https://www.linkedin.com/company/haya-therapeutics

Twitter: https://twitter.com/HAYA_lncRNA

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/haya-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/226594-36